Risk of vascular events in patients with polymyalgia rheumatica

CMAJ

Volumn 186, Issue 13, 2014, Pages E495-E501

  Hancock, Adam T ^a   Mallen, Christian D ^a   Muller, Sara ^a   Belcher, John ^a   Roddy, Edward ^a   Helliwell, Toby ^a   Hider, Samantha L ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ADULT; AGE; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT IDENTIFICATION; PERIPHERAL VASCULAR DISEASE; RHEUMATIC POLYMYALGIA; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE; VERY ELDERLY; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPLICATION; FACTUAL DATABASE; KAPLAN MEIER METHOD; PERIPHERAL VASCULAR DISEASES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VASCULAR DISEASES;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PERIPHERAL VASCULAR DISEASES; POLYMYALGIA RHEUMATICA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR DISEASES;

EID: 84907167643     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.140266     Document Type: Article

References (38)

1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
2. Roifman I, Beck PL, Anderson TJ, et al. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011;27:174-82.
3. Bengtsson C, Ohman ML, Nived O, et al. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 2012;21:452-9.
4. Clarson L, Chandratre P, Hider S, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2013 Dec. 17. (Epub ahead of print)
5. Atzeni F, Turiel M, Boccassini L, et al. Cardiovascular involvement in psoriatic arthritis. Reumatismo 2011;63:148-54.
6. Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and metaanalysis. Arthritis Care Res (Hoboken) 2011;63:557-63.
7. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46:1372-4.
8. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 2009;48:436-9.
9. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
10. Michet CJ, Matteson EL. Polymyalgia rheumatica. BMJ 2008;336:765-9.
11. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:633-9.
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
13. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J Cardiol 2010;26(Suppl A):41A-4A.
14. Mackie SL, Hensor EM, Morgan AW, et al. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis 2014;73:143-8.
15. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
16. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-8.
17. Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007;57:279-86.
18. Hancock AT, Mallen CD, Belcher J, et al. The association between polymyalgia rheumatica and vascular disease; a systematic review. Arthritis Care Res (Hoboken) 2012;64:1301-5.
19. Kremers HM, Reinalda MS, Crowson CS, et al. Direct medical costs of polymyalgia rheumatica. Arthritis Rheum 2005; 53:578-84.
20. Warrington KJ, Jarpa EP, Crowson CS, et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population- based cohort study. Arthritis Res Ther 2009;11:R50.
21. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995;34:261-4.
22. Uddhammar A, Eriksson AL, Nyström L, et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737-42.
23. Andersson R, Malmvall BE, Bengtsson BA. Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study of 90 patients treated with corticosteroids. Acta Med Scand 1986;220:361-4.
24. Bengtsson BA, Malmvall BE. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 1981;209:337-45.
25. Myklebust G, Wilsgaard T, Jacobsen BK, et al. Causes of death in polymyalgia rheumatica. A prospective longitudinal study of 315 cases and matched population controls. Scand J Rheumatol 2003;32:38-41.
26. Pfadenhauer K, Esser M, Berger K. Vertebrobasilar ischemia and structural abnormalities of the vertebral arteries in active temporal arteritis and polymyalgia rheumatic - an ultrasonographic case-control study. J Rheumatol 2005;32:2356-60.
27. Barraclough K, Liddell WG, du Toit J, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Fam Pract 2008;25:328-33.
28. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128-36.
29. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
30. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006;65:1093-8.
31. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
32. Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179-84.
33. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980;48:817-38.
34. Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 2009;23:31-40.
35. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70.
36. Svensson B, Hafström I. Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA. Clin Exp Rheumatol 2011;29(Suppl 68): S63-7.
37. Dasgupta B, Borg FA, Hassan N, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010;49:186-90.
38. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012;71:484-92.